1-哌嗪基乙腈 | 58619-56-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-哌嗪基乙腈
• 英文名称: 2-(piperazin-1-yl)acetonitrile
• 英文别名: 2-piperazin-1-ylacetonitrile
• CAS: 58619-56-0
• 化学式: C₆H₁₁N₃
• mdl: MFCD09028374
• 分子量: 125.173
• InChiKey: XHOHVIKZCDXJNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  39.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-哌嗪基乙腈 在 lithium aluminium tetrahydride 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 2-[4-(3-phenothiazin-10-ylpropyl)-piperazin-1-yl]ethylamine
  参考文献：
  名称：

  A Chimeric Ligand Approach Leading to Potent Antiprion Active Acridine Derivatives:  Design, Synthesis, and Biological Investigations

  摘要：

  Human transmissible neurodegenerations including Creutzfeldt-Jakob disease are unique, since they are caused by prions, an infectious agent that replicates without nucleic acids but instead by inducing conversion of a host-resident normal prion protein to a misfolded conformational isoform. For pharmacotherapy of these unusual diseases, tricyclic heterocyclic compounds such as quinacrine have been considered, but with ambiguous success in vivo, so far. On the basis of the synergistic antiprion effects of quinacrine and iminodibenzyl derivatives, we introduce a novel class of potential pharmaceuticals representing structural chimeras of quinacrine and imipramine analogues. We describe the chemical synthesis and bioassays of a focused library of these compounds. The most potent target compound 2a revealed an EC50 value of 20 nM determined with a cell model of prion disease, thus substantially improving the antiprion efficacy of quinacrine.

  DOI：

  10.1021/jm060773j
• 作为产物：
  描述：

  1-benzyloxycarbonyl-4-cyanomethylpiperazine 在 palladium dihydroxide 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以65%的产率得到1-哌嗪基乙腈
  参考文献：
  名称：

  A Chimeric Ligand Approach Leading to Potent Antiprion Active Acridine Derivatives:  Design, Synthesis, and Biological Investigations

  摘要：

  Human transmissible neurodegenerations including Creutzfeldt-Jakob disease are unique, since they are caused by prions, an infectious agent that replicates without nucleic acids but instead by inducing conversion of a host-resident normal prion protein to a misfolded conformational isoform. For pharmacotherapy of these unusual diseases, tricyclic heterocyclic compounds such as quinacrine have been considered, but with ambiguous success in vivo, so far. On the basis of the synergistic antiprion effects of quinacrine and iminodibenzyl derivatives, we introduce a novel class of potential pharmaceuticals representing structural chimeras of quinacrine and imipramine analogues. We describe the chemical synthesis and bioassays of a focused library of these compounds. The most potent target compound 2a revealed an EC50 value of 20 nM determined with a cell model of prion disease, thus substantially improving the antiprion efficacy of quinacrine.

  DOI：

  10.1021/jm060773j

文献信息

• 脂环胺类萘酰亚胺甲硝唑衍生物及其制备方 法和应用
  申请人：西南大学

  公开号：CN107118202B

  公开（公告）日：2019-10-22

  本发明涉及脂环胺类萘酰亚胺甲硝唑衍生物及其制备方法和应用，结构如通式I或II所示，上述化合物对革兰阳性菌、革兰阴性菌和真菌都有一定的抑制活性，同时与临床药物联用能够大大提高抗菌活性。此外该类化合物杀菌速度快且耐药性发展缓慢，可用于制备抗细菌和/或抗真菌药物，还可用做细菌DNA嵌入剂；并且制备原料商业化程度高、便宜易得，制备路线短、方法简便。
• [EN] BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION<br/>[FR] BENZODIOXANNES POUR INHIBER LA PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013134226A1

  公开（公告）日：2013-09-12

  The present invention relates to compounds of formula (I) wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式（I）的化合物，其中R1至R3，A，X和n如本文所定义。式（I）的化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式（I）化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
  申请人：BYLOCK Lars Anders

  公开号：US20130236468A1

  公开（公告）日：2013-09-12

  The present invention relates to a combination comprising compounds of formula (I): wherein R 1 to R 3 , A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.

  本发明涉及一种组合物，包括式（I）的化合物： 其中R1至R3，A，X和n如本文所定义，并且另外包括一种活性剂。本发明还涉及包括这些组合物的药物组合物，以及使用这些组合物治疗各种疾病和疾病的方法。
• [EN] SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS<br/>[FR] COMPOSÉS DE (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-A] PYRIMIDINE ET IMIDAZO [1, 2-B] PYRIDAZINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE KINASES TRK
  申请人：FOCHON PHARMACEUTICALS LTD

  公开号：WO2021047584A1

  公开（公告）日：2021-03-18

  Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

  提供了某些TRK抑制剂，其药物组合物以及使用方法。
• Quinazoline derivatives with anti-tumour activity
  申请人：AstraZeneca AB

  公开号：US20040048881A1

  公开（公告）日：2004-03-11

  The invention concerns quinazoline derivatives of Formula I 1 wherein each of m, R 1 , n, R 2 and R 3 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式I的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有描述中定义的任意含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭剂的药物的过程中在固体肿瘤疾病的控制和/或治疗中的使用。